TRIDYNE Vascular Sealant
Neomend, Inc. · Decision date Dec 18, 2025
What did the FDA decide?
FDA records P150016/S027 as a supplement to PMA P150016, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 18, 2025.
FDA approval order statement
to reduce the testing frequencies of three tests for the TRIDYNE Vascular Sealant and the PROGEL Pleural Air Leak Sealant
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Dec 18, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P150016/S027
- Regulatory pathway
- PMA supplement
- Applicant
- Neomend, Inc.
- Product code
- NBE
- Decision code
- OK30
- Decision date
- Dec 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, polymerizing.
- Applicant
- Neomend, Inc.
- Product code
- NBE
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P150016/S027 received
Application receipt date recorded by FDA.
P150016/S027 · FDA decision
30-Day Notice
P150016/S028 · Related supplement
TRIDYNE Vascular Sealant
Timeline entries are records held by MedtechLedger for P150016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TRIDYNE Vascular SealantP150016/S028 | Neomend, Inc. | PMA supplement | Mar 12, 2026 | FDA |
Explore the linked device profile
Other records with product code NBE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROGEL Pleural Air Leak SealantP010047/S073 | Neomend, Inc. | PMA supplement | Mar 12, 2026 | FDA |
PROGEL Pleural Air Leak SealantP010047/S072 | Neomend, Inc. | PMA supplement | Dec 18, 2025 | FDA |
Coseal Applicator TipsP030039/S032 | Baxter Bio Science | PMA supplement | Dec 18, 2025 | FDA |
Coseal Spray SetP030039/S031 | Baxter Bio Science | PMA supplement | Aug 21, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Neomend, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 60 Technology Dr., Irvine, CA, 92618
Sources and methodology
- Original FDA record: P150016/S027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


